AAREYDRUGSPharmaceuticals
Aarey Drugs & Pharmaceuticals Ltd — Profit & Loss Statement
₹50.75
-9.78%
Aarey Drugs & Pharmaceuticals Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -0.02 Cr | -0.02 Cr | — |
| Tax Rate For Calcs | 0.34 | 0.12 | 0.37 | 0.35 | — |
| Normalized EBITDA | 12.06 Cr | 11.42 Cr | 10.24 Cr | 13.98 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | -0.05 Cr | -0.04 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | -0.05 Cr | -0.04 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 4.02 Cr | 4.68 Cr | 3.77 Cr | 6.55 Cr | — |
| Reconciled Depreciation | 1.94 Cr | 1.70 Cr | 1.57 Cr | 1.99 Cr | — |
| Reconciled Cost Of Revenue | 462.06 Cr | 381.90 Cr | 403.84 Cr | 472.05 Cr | — |
| EBITDA | 12.06 Cr | 11.42 Cr | 10.19 Cr | 13.94 Cr | — |
| EBIT | 10.12 Cr | 9.72 Cr | 8.62 Cr | 11.95 Cr | — |
| Net Interest Income | -4.02 Cr | -4.38 Cr | -0.30 Cr | -0.03 Cr | — |
| Interest Expense | 4.02 Cr | 4.38 Cr | 2.61 Cr | 1.91 Cr | — |
| Normalized Income | 4.02 Cr | 4.68 Cr | 3.80 Cr | 6.58 Cr | — |
| Net Income From Continuing And Discontinued Operation | 4.02 Cr | 4.68 Cr | 3.77 Cr | 6.55 Cr | — |
| Total Expenses | 473.64 Cr | 392.86 Cr | 410.85 Cr | 482.12 Cr | — |
| Diluted Average Shares | 2.81 Cr | 2.55 Cr | 2.54 Cr | 2.41 Cr | — |
| Basic Average Shares | 2.81 Cr | 2.55 Cr | 2.54 Cr | 2.41 Cr | — |
| Diluted EPS | 1.43 | 1.84 | 1.49 | 2.72 | — |
| Basic EPS | 1.43 | 1.84 | 1.49 | 2.72 | — |
| Diluted NI Availto Com Stockholders | 4.02 Cr | 4.68 Cr | 3.77 Cr | 6.55 Cr | — |
| Net Income Common Stockholders | 4.02 Cr | 4.68 Cr | 3.77 Cr | 6.55 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 4.02 Cr | 4.68 Cr | 3.77 Cr | 6.55 Cr | — |
| Net Income Including Noncontrolling Interests | 4.02 Cr | 4.68 Cr | 3.77 Cr | 6.55 Cr | — |
| Net Income Continuous Operations | 4.02 Cr | 4.68 Cr | 3.77 Cr | 6.55 Cr | — |
| Tax Provision | 2.08 Cr | 0.66 Cr | 2.24 Cr | 3.48 Cr | — |
| Pretax Income | 6.10 Cr | 5.34 Cr | 6.01 Cr | 10.04 Cr | — |
| Other Non Operating Income Expenses | 9.81 Cr | 6.96 Cr | 4.80 Cr | 0.58 Cr | — |
| Special Income Charges | 0.00 | 0.00 | -0.05 Cr | -0.04 Cr | — |
| Net Non Operating Interest Income Expense | -4.02 Cr | -4.38 Cr | -0.30 Cr | -0.03 Cr | — |
| Interest Expense Non Operating | 4.02 Cr | 4.38 Cr | 2.61 Cr | 1.91 Cr | — |
| Operating Income | 0.31 Cr | 2.75 Cr | 2.00 Cr | 9.49 Cr | — |
| Operating Expense | 11.58 Cr | 10.97 Cr | 7.00 Cr | 10.07 Cr | — |
| Other Operating Expenses | 5.46 Cr | 6.27 Cr | 3.38 Cr | 5.42 Cr | — |
| Depreciation And Amortization In Income Statement | 1.94 Cr | 1.70 Cr | 1.57 Cr | 1.99 Cr | — |
| Depreciation Income Statement | 1.94 Cr | 1.70 Cr | 1.57 Cr | 1.99 Cr | — |
| Selling General And Administration | 3.37 Cr | 2.28 Cr | 0.70 Cr | 1.00 Cr | — |
| Selling And Marketing Expense | 2.39 Cr | 1.19 Cr | 0.26 Cr | 0.39 Cr | — |
| General And Administrative Expense | 0.97 Cr | 1.09 Cr | 0.44 Cr | 0.61 Cr | — |
| Gross Profit | 11.88 Cr | 13.72 Cr | 9.01 Cr | 19.55 Cr | — |
| Cost Of Revenue | 462.06 Cr | 381.90 Cr | 403.84 Cr | 472.05 Cr | — |
| Total Revenue | 473.94 Cr | 395.62 Cr | 412.85 Cr | 491.61 Cr | — |
| Operating Revenue | 473.94 Cr | 395.62 Cr | 412.85 Cr | 491.61 Cr | — |
| Interest Income | — | 4.87 Cr | 2.63 Cr | 2.01 Cr | 2.43 Cr |
| Rent Expense Supplemental | — | 0.53 Cr | 0.49 Cr | 0.68 Cr | 0.67 Cr |
| Net Income Discontinuous Operations | — | 0.00 | 0.00 | 0.00 | — |
| Write Off | — | 0.02 Cr | 0.05 Cr | 0.04 Cr | 0.00 |
| Total Other Finance Cost | — | 0.07 Cr | 0.32 Cr | 0.13 Cr | 0.11 Cr |
| Interest Income Non Operating | — | 4.87 Cr | 2.63 Cr | 2.01 Cr | 2.43 Cr |
| Rent And Landing Fees | — | 0.53 Cr | 0.49 Cr | 0.68 Cr | 0.67 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Aarey Drugs & Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.